Actualités

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

If you are asking whether Bristol-Myers Squibb at around US$56.95 is offering fair value or a potential bargain, the starting point is to look past the headline share price and into how it stacks up against several valuation checks. The stock has had mixed returns, with a 2.2% decline over the past week and a 4.4% decline over the last month, but it is up 6.5% year to date and 25.7% over the past year, which may change how investors are thinking about both risk and opportunity. Recent...

BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering later stage development. BioNTech plans to consolidate its manufacturing footprint to support operational efficiency and R&D investment. BioNTech, known for its mRNA technology, is pushing further into oncology as it works with Bristol Myers Squibb on multiple pivotal studies. For readers tracking...

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.

Cytokinetics stock surged Tuesday on positive results in a key heart disease where its chief rival, Bristol's Camzyos, previously failed.